Ralliant Corporation $RAL Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC reduced its holdings in Ralliant Corporation (NYSE:RAL) by 5.3% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 230,081 shares of the company’s stock after selling 12,819 shares during the quarter. Allspring Global Investments Holdings LLC owned approximately 0.21% of Ralliant worth $9,801,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of RAL. Viking Global Investors LP bought a new position in shares of Ralliant during the second quarter valued at approximately $257,200,000. State Street Corp bought a new stake in shares of Ralliant in the 2nd quarter worth approximately $213,096,000. Millennium Management LLC boosted its position in Ralliant by 172.4% during the 4th quarter. Millennium Management LLC now owns 4,973,001 shares of the company’s stock valued at $253,175,000 after purchasing an additional 3,147,660 shares during the period. Norges Bank acquired a new position in Ralliant during the 4th quarter valued at approximately $124,687,000. Finally, Invesco Ltd. grew its stake in Ralliant by 90.1% during the 3rd quarter. Invesco Ltd. now owns 3,871,690 shares of the company’s stock worth $169,309,000 after buying an additional 1,835,128 shares during the last quarter.

Analyst Ratings Changes

RAL has been the topic of a number of recent research reports. BMO Capital Markets assumed coverage on Ralliant in a research note on Monday. They issued a “market perform” rating and a $78.00 target price on the stock. Oppenheimer upped their price target on shares of Ralliant from $50.00 to $65.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 13th. Morgan Stanley increased their price objective on shares of Ralliant from $68.00 to $85.00 and gave the stock an “overweight” rating in a report on Tuesday, June 23rd. Weiss Ratings reiterated a “sell (d)” rating on shares of Ralliant in a research report on Monday, May 4th. Finally, Royal Bank Of Canada boosted their target price on shares of Ralliant from $64.00 to $71.00 and gave the company a “sector perform” rating in a research note on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $73.00.

Ralliant Stock Performance

Shares of RAL opened at $70.12 on Thursday. The firm has a market capitalization of $7.85 billion and a PE ratio of -6.41. The company has a quick ratio of 1.05, a current ratio of 1.61 and a debt-to-equity ratio of 0.73. The firm has a 50-day moving average price of $66.03 and a 200 day moving average price of $53.55. Ralliant Corporation has a 52-week low of $37.27 and a 52-week high of $75.41.

Ralliant (NYSE:RAL) last released its quarterly earnings results on Tuesday, May 12th. The company reported $0.57 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.08. The company had revenue of $534.60 million for the quarter. Ralliant had a negative net margin of 58.55% and a positive return on equity of 12.49%. The business’s revenue for the quarter was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. On average, sell-side analysts anticipate that Ralliant Corporation will post 2.64 earnings per share for the current fiscal year.

Ralliant Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 23rd. Shareholders of record on Monday, June 8th were given a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date was Monday, June 8th. Ralliant’s dividend payout ratio is -1.83%.

Ralliant Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.